• Yanjun Zhong, Lishu Zhao, Guobao Wu, Chunhong Hu, Chenfang Wu, Min Xu, Haiyun Dong, Quan Zhang, Guyi Wang, Bo Yu, Jianlei Lv, Chao Wu, Siye Zhang, Chenghui Cao, Long Shu, Yue Pan, Xianling Liu, and Fang Wu.
• Department of Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
• J. Int. Med. Res. 2020 Dec 1; 48 (12): 300060520979151.

ObjectiveAssociation of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) use with coronavirus disease 2019 (COVID-19) remains controversial. We aimed to investigate the impact of ACEI/ARB use on all-cause mortality in severe COVID-19 patients with hypertension.MethodsWe enrolled 650 COVID-19 patients from Changsha and Wuhan city between 17 January 2020 and 8 March 2020. Demographic, clinical characteristics, and outcomes were collected. Multivariable analysis and propensity-score matching were performed to assess the impact of ACEI/ARB therapy on mortality.ResultsAmong the 650 patients, 126 who had severe COVID-19 concomitant with hypertension were analyzed. The average age was 66 years and 56 (44.4%) were men. There were 37 ACEI/ARB users and 21 in-hospital deaths (mortality rate, 16.7%). Male sex (odds ratio [OR], 5.13; 95% confidence interval [CI], 1.75 to 17.8), but not ACEI/ARB use (OR, 1.09; 95%CI, 0.31 to 3.43), was an independent risk factor for mortality in severe COVID-19 patients with hypertension. After propensity-score matching, 60 severe COVID-19 patients were included and no significant correlation between use of ACEI/ARB and mortality was observed.ConclusionsThere was no significant association of ACEI/ARB use with mortality in severe COVID-19 patients with hypertension. These findings support the continuation of ACEI/ARB therapy for such patients.

39 keywords...

hide…